Hôpital Beaujon
Hôpital Beaujon
Clichy, France16 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pathophysiological Explorations of Red Blood Cells | erythrocyte disorder | Recruiting | Not stated | 2026-09-09 | NCT03541525 | |
| A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cirrhosis of liver, liver disorder, metabolic dysfunction-associated steatohepatitis | Active, not recruiting | Phase 3 | 2026-07-08 | NCT05500222 | |
| Patient-reported Outcome and Patient-reported Experience After Status Epilepticus | Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Status Epilepticus, nervous system disorder, visual epilepsy | Recruiting | Not stated | 2026-07-07 | NCT06100978 | |
| Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Active, not recruiting | Phase 2 | 2026-06-22 | NCT04727307 | |
| Personalize (Signature Driven) Neoadjuvant Chemotherapy Trial for Patients With Resectable Borderline Pancreatic Ductal Adenocarcinoma. | Borderline Resectable Pancreatic Ductal Adenocarcinoma | Not yet recruiting | Phase 2 | 2026-06-11 | NCT07616362 | |
| A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease | Active, not recruiting | Phase 3 | 2026-06-01 | NCT03900429 | |
| Perioperative Hemostasis Management in Liver Transplantation | Liver Transplant; Complications | Recruiting | Not stated | 2026-04-02 | NCT06257407 | |
| COLPAC (RaDiCo Cohort) (RaDiCo-COLPAC) | gallbladder disease 1 | Active, not recruiting | Not stated | 2026-02-12 | NCT05961826 | |
| MPS (RaDiCo Cohort) (RaDiCo-MPS) | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Lysosomal Storage Diseases, Nervous System, Mucopolysaccharidosis I, Mucopolysaccharidosis III, Neurobehavioral Manifestations, Neurologic Manifestations, Nutritional and Metabolic Diseases, Skin and Connective Tissue Diseases, Sulfatidosis, X-linked disease, brain disorder, central nervous system disorder, connective tissue disorder, cutaneous mucinosis, hereditary disease, inborn carbohydrate metabolic disorder, inborn errors of metabolism, inherited neurodegenerative disorder, intellectual disability, lysosomal lipid storage disorder, lysosomal storage disease, metabolic disease, mucopolysaccharidosis, mucopolysaccharidosis type 2, mucopolysaccharidosis type 4, mucopolysaccharidosis type 6, mucopolysaccharidosis type 7, mucosulfatidosis, nervous system disorder, sphingolipidosis | Recruiting | Not stated | 2026-02-11 | NCT06036693 | |
| Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01) | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, adenocarcinoma, carcinoma, epithelial neoplasm, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, primitive neuroectodermal tumor | Not yet recruiting | Phase 2 | 2026-01-13 | NCT07337447 | |
| Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer | neoplasm | Recruiting | Phase 2 | 2025-12-05 | NCT04570943 | |
| Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status. | Metastatic Pancreatic Adenocarcinoma | Active, not recruiting | Phase 2 | 2025-07-25 | NCT04348045 | |
| Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, adenocarcinoma, carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 2 | 2025-07-23 | NCT04268121 | |
| Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy. | Advanced Biliary Tract Carcinoma | Active, not recruiting | Phase 2 | 2025-07-23 | NCT03704480 | |
| Management of Symptomatic Advanced Pancreatic Adenocarcinoma | Management Supportive Care Program; Pancreas | Active, not recruiting | Not applicable | 2025-06-13 | NCT02979483 | |
| Prognostic and Predictive Markers of Treatment Response in Patients With PAC. | pancreatic adenocarcinoma | Recruiting | Not stated | 2025-03-25 | NCT05776342 |